MapLight Therapeutics (MPLT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.97
- Estimate
- -$1.11
- Surprise
- +12.3%
- Score at report (before → after)
- 4.5 → 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
MapLight Therapeutics (MPLT) reported a narrower loss than forecast — adjusted EPS of -$0.97 against the -$1.11 estimate (a 12.3% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Sell (4.5/10) to Hold at 4.6/10 after the report.
Coverage in the report window
- MapLight Therapeutics Enters $100M At-The-Market Equity Offering Agreement With Leerink Partners — benzinga, 2026-11-16
- MapLight Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-16
- MapLight Therapeutics Q3 EPS $(0.97) Beats $(1.16) Estimate — benzinga, 2026-11-16
Where TrendMatrix's rating stands now
TrendMatrix currently rates MPLT Hold at 4.6/10.
1 of the last 4 quarters beat the estimate; this quarter's +12.3% surprise compares with a -3.9% four-quarter average.
What argues against it
- Concentration risk — Pipeline: ML-007C-MA (lead product candidate)
- DATA_ISSUE: analyst_target_implausible (raw $26.54 vs price $6.90 — ratio 3.8×). Rejected, falling back to technical TP.
- Market cap $383M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.90
- Price target
- $8.41
- Stop
- $6.42
- Upside to target
- +21.9%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
MPLT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $383.5M
- P/E (fwd)
- -1.9
- 52-week range
- $6.06–$40.43
- Off 52-week high
- 82.9%
- RSI (14)
- 35
- Volume vs avg
- 0.87×
- Score today
- 4.6/10